Comparing Disease Severity Before and After Infliximab Treatment in Children with Inflammatory Bowel Disease (2015 - 2020) at a Tertiary Center
| Author | Naghi Dara | en |
| Author | Amirhossein Hosseini | en |
| Author | Yasaman Zarinfar | en |
| Author | Faezeh Shojaei | en |
| Author | Arshia Dara | en |
| Author | Saleheh Tajalli | en |
| Author | Farid Imanzadeh | en |
| Author | Negar Imanzadeh | en |
| Author | Aliakbar Sayyari | en |
| Author | Mahmoud Hajipour | en |
| Orcid | Naghi Dara [0000-0002-1881-8893] | en |
| Orcid | Amirhossein Hosseini [0000-0001-8103-8833] | en |
| Orcid | Yasaman Zarinfar [0000-0002-3559-6022] | en |
| Orcid | Arshia Dara [0009-0007-6836-4897] | en |
| Orcid | Saleheh Tajalli [0000-0002-2045-6430] | en |
| Orcid | Farid Imanzadeh [0000-0003-0223-6431] | en |
| Orcid | Aliakbar Sayyari [0000-0002-2125-7601] | en |
| Orcid | Mahmoud Hajipour [0000-0001-8187-9114] | en |
| Issued Date | 2026-01-31 | en |
| Abstract | Background: The prevalence of inflammatory bowel disease (IBD) in children is rising globally. Infliximab, a biological drug, has emerged as a treatment option. Objectives: This study evaluates the impact of infliximab on IBD severity in children. Methods: This retrospective study analyzed infliximab’s efficacy in children with IBD from 2015 - 2020. Patients were categorized as Crohn’s disease, ulcerative colitis (UC), or indeterminate colitis, and disease severity was scored using established criteria. A score of 30 or higher in Crohn's disease was interpreted as moderate to severe, and a score below 10 indicated that the disease was silent and inactive. In UC, a score above 65 was severe, 30 - 64 was moderate, 10 - 29 was mild, and below 10 indicated inactive disease. A decrease of 12.5 points after starting the treatment was considered a suitable response to the drug. The data were analyzed with SPSS 26 software. Results: The study included 28 pediatric IBD patients, evenly split by gender, with an average age of 12.3. Disease severity decreased significantly post-infliximab treatment: From 66.20 ± 14.7 initially to 6.5 at 14 weeks. The severity reduction varied significantly across disease types (P = 0.02), with no demographic-based differences observed. Conclusions: Infliximab treatment markedly reduced IBD severity, demonstrating its effectiveness regardless of demographic factors. | en |
| DOI | https://doi.org/10.5812/apid-159828 | en |
| Keyword | Infliximab | en |
| Keyword | Inflammatory Bowel Disease | en |
| Keyword | Crohn Disease | en |
| Keyword | Colitis, Ulcerative | en |
| Keyword | Disease Severity | en |
| Publisher | Brieflands | en |
| Title | Comparing Disease Severity Before and After Infliximab Treatment in Children with Inflammatory Bowel Disease (2015 - 2020) at a Tertiary Center | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- apid-14-1-159828-publish-pdf.pdf
- Size:
- 133.58 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF